RT Journal Article
SR Electronic
T1 The IGNITE Trial: Participant Recruitment Lessons Prior to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20107458
DO 10.1101/2020.05.19.20107458
A1 Vidoni, Eric D.
A1 Szabo-Reed, Amanda
A1 Kang, Chaeryon
A1 Perales-Puchalt, Jaime
A1 Shaw, Ashley R.
A1 Grove, George
A1 Hamill, Morgan
A1 Henry, Donovan
A1 Burns, Jeffrey M.
A1 Hillman, Charles
A1 Kramer, Arthur F.
A1 McAuley, Edward
A1 Erickson, Kirk I.
YR 2020
UL http://medrxiv.org/content/early/2020/05/25/2020.05.19.20107458.abstract
AB Full and diverse participant enrollment is critical to the success and generalizability of all large-scale Phase III trials. Recruitment of sufficient participants is among the most significant challenges for many studies. The novel SARS-CoV-2 coronavirus pandemic has further changed and challenged the landscape for clinical trial execution, including screening and randomization. The Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE) study has been designed as the most comprehensive test of aerobic exercise effects on cognition and brain health. Here we assess recruitment into IGNITE prior to the increased infection rates in the United States, and examine new challenges and opportunities for recruitment with a goal of informing the remaining required recruitment as infection containment procedures are lifted. The results may assist the design and implementation of recruitment for future exercise studies, and outline opportunities for study design that are flexible in the face of emerging threats.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02875301Funding StatementR01 AG053952; R01 AG053952 04S1; P30 AG035982 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request from the principal investigator, kiericks@pitt.edu.